Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) reported a net loss of £1.84 million for the six months ended June 30, 2026, a significant improvement from the £3.81 million loss recorded in the same period last year.

The clinical-stage biopharmaceutical company saw its cash balance decline to £3.23 million at the end of the period, down from £8.53 million at December 31, 2025. The reduction was driven by operating cash outflows of £4.61 million and investing activities totaling £0.63 million.

Financial Performance

Revenue remained at nil for both periods, consistent with the company’s pre-commercial status. The narrowing net loss was primarily supported by a substantial gain on equity-settled derivative financial liabilities, which contributed £2.38 million to finance income in 1H26 compared to just £0.15 million in 1H25. This gain arose from a fall in the Biodexa share price.

Research and development costs increased by 75% to £2.92 million from £1.67 million in the prior year. This rise reflects heightened expenditure on the Serenta Phase 3 trial for Familial Adenomatous Polyposis (FAP) and manufacturing costs associated with the newly in-licensed MTX240 program. Conversely, administrative costs decreased by 27% to £1.74 million, largely due to favorable foreign exchange movements.

Pipeline Progress

Operationally, Biodexa advanced its core programs during the half:

• In-licensed MTX240 from Otsuka Pharmaceutical Co., Limited in February 2026 with a nominal upfront payment.
• Launched a global Early Access Program for eRapa for FAP patients through a partnership with Tanner Pharma Group in March 2026.
• Secured Health Canada approval to expand the Serenta trial into Canada in June 2026.

As of the publication date, 92 of the planned 168 subjects have been enrolled in the Serenta trial. Post-period end, on July 1, 2026, the company completed a fundraise raising gross proceeds of $3.5 million through a combination of a registered direct offering, warrant inducement, and PIPE offering.

What the Numbers Show

The reported net loss improvement is non-operational in nature. While the headline loss narrowed by nearly 52%, this was driven almost entirely by the £2.38 million gain on derivative liabilities rather than operational efficiency. Operating loss actually widened slightly to £4.21 million from £4.02 million in the prior year, underscoring that the core business burn rate remains elevated despite administrative cost savings.

Going Concern & Financing

The directors highlighted that the group’s future viability depends on its ability to raise cash from financing activities. With an accumulated deficit of £157.60 million, the company faces material uncertainty regarding its ability to continue as a going concern without further funding. Forecasts indicate additional financing will be required during Q4 2026. As of June 30, 2026, $26.08 million remains undrawn from the company’s $35 million Equity Line of Credit.

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) announced that it has exceeded the halfway mark in subject recruitment for its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP). As of August 19, 2026, 87 of the planned 168 subjects have been recruited into the Serenta trial (NCT06950385). This milestone confirms the feasibility of the enrollment timeline for the double-blind, placebo-controlled study.

The trial is currently recruiting at 29 clinical sites across the US and five European countries. Three additional sites in Canada are expected to be initiated shortly. The protocol involves randomizing subjects 2:1 to drug or placebo. The company plans to conduct a futility analysis after 25 Progression Free Survival (PFS) events and will lock the database after 75 PFS events. The endpoint is composite, defining the nature of these PFS events.

What the Numbers Show

The recruitment of 87 subjects against a target of 168 represents more than 50% completion of the enrollment phase. With 29 sites already active and three more planned in Canada, the infrastructure supports the remaining 81 enrollments. The reliance on a composite endpoint for PFS suggests a focus on multiple clinical markers of disease progression rather than a single binary outcome.

Trial Design and Funding

eRapa is a proprietary oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor. The Phase 3 program is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Data from an open-label Phase 2 trial were presented at Digestive Disease Week and InSIGHT 2024 in May and June 2024, respectively. Based on those data, Biodexa initiated the current registrational trial.

Disease Context

Familial Adenomatous Polyposis is characterized by the proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option for treating FAP patients; standard care remains active surveillance and surgical resection. If untreated, FAP typically leads to cancer of the colon and/or rectum. The reported incidence is one in 5,000 to 10,000 in the US and one in 11,300 to 37,600 in Europe. eRapa has received Orphan Drug Designation in both the US and Europe.

Stephen Stamp, Chief Executive Officer of Biodexa, stated that the company thanks its collaborators at leading FAP treatment centers for helping drive recruitment ahead of competition. Biodexa’s other development programs include MTX240 for Gastrointestinal Stromal Tumors and tolimidone for type 1 diabetes.